Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Life Sciences Virtual Investor Forum 2025
18 slides from Amplia Therapeutics's conference presentation, Dec 11, 2025
Slide 1: Additional Confirmed Response Reported as Part of Amplia Investor Presentation
11 DECEMBER 2025 ASX RELEASE ADDITIONAL CONFIRMED RESPONSE REPORTED AS PART OF AMPLIA INVESTOR PRESENTATION HIGHLIGHTS For personal use only • An additional confirmed partial response has been recorded in the ongoing ACCENT trial • This brings the confirmed Objective Response Rate to 35% • Updated d
Slide 2: Contacts, About Amplia Therapeutics and About Narmafotinib
Investor Contact: Media Contact: Dr Chris Burns H^CK Director, Haley Chartres Chief Executive Officer haley@hck.digital chris@ampliatx.com +61 423 139 163 U.S. Contact: U.S. Media: Robert Giordano media@ampliatx.com rjgiordano@ggrouplifesciences.com +1 917 327 3938 About Amplia Therapeutics Limited
Slide 3: Life Sciences Virtual Investor Forum
For personal use only Life Sciences Virtual Investor Forum 11 December 2025 Chris Burns PhD ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 1
Slide 4: Disclaimer
DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 operat
Slide 5: Executive Summary
EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK Lead drug narmafotinib is best-in-class FAK inhibitor in development For personal use only Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer New trial of narmafotinib in p
Slide 6: Board + Management
BOARD + MANAGEMENT World-class experts BOARD SENIOR MANAGEMENT For personal use only Rhiannon Jones PhD GAICD COO Warwick Tong Robert Peach Jane Bell Chris Burns* MB ChB MPP GAICD PhD LLB LLM (Lond) FAICD PhD GAICD Director CEO and MD Jason Lickliter Chair Director MBBS FRACP CMO Tim Luscombe BCom C
Slide 7: Metastatic Pancreatic Cancer
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes 5Y Survival Limited Treatment Options Median Progression Median Overall Treatment Tolerability For personal use only Free Survival Survival Gemcitabine + nab-paclitaxel 5.5 months 8.5 months 3% (MPACT study) FOLFIRINOX 6.4
Slide 8: FAK Inhibition in Cancer
FAK INHIBITION IN CANCER FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition For personal use only FAK levels are elevated in pancreatic cancer Anti-proliferative Synergy with Correlate with worse patient outcome Reduces cells’ ability chemotherapies to proliferate Enhances activit
Slide 9: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB A Potent and Selective FAK Inhibitor For personal use only Drug-like small molecule Potent activity in laboratory models of human pancreatic cancer Once a day oral dosing by capsule Storage at room temperature Safe to combine with other medicines No evidence of drug-drug interactions Ev
Slide 10: ACCENT Trial in Pancreatic Cancer
ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea OBJECTIVE Demographics To determine safety and efficacy of narmafotinib For personal use only Patient # (total study) 55 in combination with gemcitabine and nab- Geographic area (%) Australia (44%) / Korea (56%) paclitaxel Pa
Slide 11: ACCENT Trial Topline Data
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Median Progression Free Survival (mPFS) data All ACCENT patients @ 400 mg (n = 64) For personal use only Currently determined at 7.6 months - substantially better than chemotherapy alone (5.5 months) Improvement ov
Slide 12: ACCENT Trial Interim Data
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability Excellent response rate observed ACCENT Trial MPACT Trial (Narmafotinib/Gemcitabine/ (Gemcitabine/ For personal use only nab-paclitaxel) nab-paclitaxel) 1 confirmed Complete Response (CR) CR 2% 0.2% 18 confirmed Pa
Slide 13: ACCENT Trial Topline Data: Tolerability
ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent tolerability observed to date Narmafotinib treatment results in negligible extra patient burden For personal use only Adverse Events (Grade 3 or above) Narmafotinib + Gem/Abr (ACCENT; N=55) Gem/Abr (MPACT
Slide 14: The Amplia Advantage
THE AMPLIA ADVANTAGE Three critical features For personal use only Efficacy Narmafotinib Tolerability Durability 12
Slide 15: Future Opportunities
FUTURE OPPORTUNITIES FAK inhibition will enhance multiple therapeutic strategies Narmafotinib (FAK inhibition) For personal use only CHEMOTHERAPY IMMUNOTHERAPIES Clinical and preclinical data incl. Preclinical data ACCENT study KRAS INHIBITORS RADIOTHERAPY Preclinical data, incl. Published data coll
Slide 16: AMPLICITY Trial in mPDAC
AMPLICITY TRIAL in mPDAC Phase 1b/2a study in the US and Australia Moving from intermittent to daily dosing OBJECTIVE To determine safety and efficacy of narmafotinib For personal use only narmafotinib when added to FOLFIRINOX in newly diagnosed metastatic patients FOLFIRINOX TRIAL DESIGN Dose escal
Slide 17: Future Milestones
FUTURE MILESTONES Key deliverables ACCENT (NARMAFOTINIB + GEMCITABINE + ABRAXANE) Recruitment Response Topline Mature Trial Phase 2b/3 For personal use only completed rate update data (PFS) data completion Initiation 2025 2026 2027 Trial Sites First patient Dose Complete dose Initiate 2 dose Complet
Slide 18: Thank You
For personal use only THANK YOU Chris Burns PhD chris@ampliatx.com Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF info@ampliatx.com ampliatx.com 16
Amplia Therapeutics — Life Sciences Virtual Investor Forum 2025 on 6ix